TY - JOUR
T1 - Early Diagnosis and Intervention in Cystic Fibrosis
T2 - Imagining the Unimaginable
AU - Coverstone, Andrea M.
AU - Ferkol, Thomas W.
N1 - Funding Information:
The authors were supported by National Institutes of Health (NIH) awards U54HL096458 (TF) and R21AI46999 (TF) and the Cystic Fibrosis Foundation.
Publisher Copyright:
© Copyright © 2021 Coverstone and Ferkol.
PY - 2021/1/11
Y1 - 2021/1/11
N2 - Cystic fibrosis is the most common life-shortening genetic disease affecting Caucasians, clinically manifested by fat malabsorption, poor growth and nutrition, and recurrent sinopulmonary infections. Newborn screening programs for cystic fibrosis are now implemented throughout the United States and in many nations worldwide. Early diagnosis and interventions have led to improved clinical outcomes for people with cystic fibrosis. Newer cystic fibrosis transmembrane conductance regulator potentiators and correctors with mutation-specific effects have increasingly been used in children, and these agents are revolutionizing care. Indeed, it is possible that highly effective modulator therapy used early in life could profoundly affect the trajectory of cystic fibrosis lung disease, and primary prevention may be achievable.
AB - Cystic fibrosis is the most common life-shortening genetic disease affecting Caucasians, clinically manifested by fat malabsorption, poor growth and nutrition, and recurrent sinopulmonary infections. Newborn screening programs for cystic fibrosis are now implemented throughout the United States and in many nations worldwide. Early diagnosis and interventions have led to improved clinical outcomes for people with cystic fibrosis. Newer cystic fibrosis transmembrane conductance regulator potentiators and correctors with mutation-specific effects have increasingly been used in children, and these agents are revolutionizing care. Indeed, it is possible that highly effective modulator therapy used early in life could profoundly affect the trajectory of cystic fibrosis lung disease, and primary prevention may be achievable.
KW - corrector
KW - cystic fibrosis
KW - cystic fibrosis transmembrane conductance regulator
KW - immunoreactive trypsin(ogen)
KW - newborn screening
KW - potentiator
KW - sweat chloride test
UR - http://www.scopus.com/inward/record.url?scp=85099973620&partnerID=8YFLogxK
U2 - 10.3389/fped.2020.608821
DO - 10.3389/fped.2020.608821
M3 - Review article
C2 - 33505947
AN - SCOPUS:85099973620
SN - 2296-2360
VL - 8
JO - Frontiers in Pediatrics
JF - Frontiers in Pediatrics
M1 - 608821
ER -